Immuron Limited (ANW.F)
| Previous Close | 0.0590 |
| Open | 0.0590 |
| Bid | 0.0550 x 0 |
| Ask | 0.0740 x 0 |
| Day's Range | 0.0585 - 0.0585 |
| 52 Week Range | 0.0405 - 0.0991 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 15.028M |
| Beta (5Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0130 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) application for a new oral therapeutic targeting Cam
- GlobeNewswire
Immuron North American Travelan® Sales up 494% and Global sales up 431%
Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce the FY22 sales results o
- GlobeNewswire
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has received notification of the Intent to Grant a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the inte
